Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3325175rdf:typepubmed:Citationlld:pubmed
pubmed-article:3325175lifeskim:mentionsumls-concept:C0021311lld:lifeskim
pubmed-article:3325175lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:3325175lifeskim:mentionsumls-concept:C0001824lld:lifeskim
pubmed-article:3325175lifeskim:mentionsumls-concept:C0002499lld:lifeskim
pubmed-article:3325175lifeskim:mentionsumls-concept:C0004521lld:lifeskim
pubmed-article:3325175lifeskim:mentionsumls-concept:C0007559lld:lifeskim
pubmed-article:3325175lifeskim:mentionsumls-concept:C0031955lld:lifeskim
pubmed-article:3325175lifeskim:mentionsumls-concept:C1709160lld:lifeskim
pubmed-article:3325175pubmed:issue6lld:pubmed
pubmed-article:3325175pubmed:dateCreated1988-4-7lld:pubmed
pubmed-article:3325175pubmed:abstractTextSixty granulocytopenic patients (granulocytes less than 1000/mm3) affected with solid tumors, previously submitted to antiblastic therapy and with infections, were treated with three antibiotic combinations: amikacin + ceftazidime, amikacin + piperacillin or amikacin + aztreonam. In 68% of the cases the infections were due to gram-negative and in the remaining 32% to gram-positive microorganisms. The results obtained with the three treatments show a slight but significant statistical difference (p less than 0.05), due to the greater efficacy of the amikacin + ceftazidime combination on gram-positive and amikacin + aztreonam on gram-negative bacteria.lld:pubmed
pubmed-article:3325175pubmed:languageenglld:pubmed
pubmed-article:3325175pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3325175pubmed:citationSubsetIMlld:pubmed
pubmed-article:3325175pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3325175pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3325175pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3325175pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3325175pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3325175pubmed:statusMEDLINElld:pubmed
pubmed-article:3325175pubmed:monthDeclld:pubmed
pubmed-article:3325175pubmed:issn0392-906Xlld:pubmed
pubmed-article:3325175pubmed:authorpubmed-author:AmeglioFFlld:pubmed
pubmed-article:3325175pubmed:authorpubmed-author:CasaliAAlld:pubmed
pubmed-article:3325175pubmed:authorpubmed-author:Gallo...lld:pubmed
pubmed-article:3325175pubmed:authorpubmed-author:GionfraTTlld:pubmed
pubmed-article:3325175pubmed:authorpubmed-author:PaolettiGGlld:pubmed
pubmed-article:3325175pubmed:authorpubmed-author:TonachellaRRlld:pubmed
pubmed-article:3325175pubmed:issnTypePrintlld:pubmed
pubmed-article:3325175pubmed:volume6lld:pubmed
pubmed-article:3325175pubmed:ownerNLMlld:pubmed
pubmed-article:3325175pubmed:authorsCompleteYlld:pubmed
pubmed-article:3325175pubmed:pagination440-4lld:pubmed
pubmed-article:3325175pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3325175pubmed:meshHeadingpubmed-meshheading:3325175-...lld:pubmed
pubmed-article:3325175pubmed:meshHeadingpubmed-meshheading:3325175-...lld:pubmed
pubmed-article:3325175pubmed:meshHeadingpubmed-meshheading:3325175-...lld:pubmed
pubmed-article:3325175pubmed:meshHeadingpubmed-meshheading:3325175-...lld:pubmed
pubmed-article:3325175pubmed:meshHeadingpubmed-meshheading:3325175-...lld:pubmed
pubmed-article:3325175pubmed:meshHeadingpubmed-meshheading:3325175-...lld:pubmed
pubmed-article:3325175pubmed:meshHeadingpubmed-meshheading:3325175-...lld:pubmed
pubmed-article:3325175pubmed:meshHeadingpubmed-meshheading:3325175-...lld:pubmed
pubmed-article:3325175pubmed:meshHeadingpubmed-meshheading:3325175-...lld:pubmed
pubmed-article:3325175pubmed:meshHeadingpubmed-meshheading:3325175-...lld:pubmed
pubmed-article:3325175pubmed:meshHeadingpubmed-meshheading:3325175-...lld:pubmed
pubmed-article:3325175pubmed:meshHeadingpubmed-meshheading:3325175-...lld:pubmed
pubmed-article:3325175pubmed:meshHeadingpubmed-meshheading:3325175-...lld:pubmed
pubmed-article:3325175pubmed:meshHeadingpubmed-meshheading:3325175-...lld:pubmed
pubmed-article:3325175pubmed:meshHeadingpubmed-meshheading:3325175-...lld:pubmed
pubmed-article:3325175pubmed:year1987lld:pubmed
pubmed-article:3325175pubmed:articleTitleAmikacin plus ceftazidime versus amikacin plus piperacillin versus amikacin plus aztreonam in infections in neoplastic patients with granulocytopenia.lld:pubmed
pubmed-article:3325175pubmed:affiliationII Division of Medical Oncology, Regina Elena Nat'l. Cancer Inst., Roma, Italy.lld:pubmed
pubmed-article:3325175pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3325175pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3325175pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3325175pubmed:publicationTypeControlled Clinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3325175lld:pubmed